Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 214-216

  Poggi, Alessandro ^a   Zocchi, Maria Raffaella ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

B1 cells; Bone morphogenetic proteins; Chronic myelogenous leukemia; SDF 1 BAFF

Indexed keywords

B CELL ACTIVATING FACTOR; CD20 ANTIGEN; CD5 ANTIGEN; IMATINIB; STROMAL CELL DERIVED FACTOR 1;

ADAPTIVE IMMUNITY; B LYMPHOCYTE ACTIVATION; BCR ABL GENE; BONE MARROW; BONE MARROW MICROENVIRONMENT; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG MECHANISM; GENE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INNATE IMMUNITY; NONHUMAN; NOTE; POINT MUTATION; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886944676     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.2.18112     Document Type: Note

References (10)

1. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukaemia. Leukemia 2009; 23:1054-61; http://dx.doi.org/10.1038/leu. 2009.38
2. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8:1018-29; http://dx.doi.org/ 10.1016/S1470-2045(07)70342-X
3. Smyth MJ. Imatinib Mesylate - Uncovering a fast track to adaptive immunity. N Engl J Med 2006; 354: 2282-4; http://dx.doi.org/10.1056/ NEJMcibr061878
4. Catellani S, Pierri I, Gobbi M, Poggi A, Zocchi MR. Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS One 2011. PLoS ONE 2011; 6:e18925; http://dx.doi.org/10.1371/journal.pone.0018925
5. Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001; 13:195-201; http://dx.doi.org/10.1016/S0952-7915(00)00204-1
6. Schwartz-Albiez R, Laban S, Eichmueller S, Kirschfink M. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? Autoimmun Rev 2008; 7:491-5; http://dx.doi.org/10. 1016/j.autrev.2008.03.012
7. Schaumann DH, Tuischer J, Ebell W, Manz RA, Lauster R. VCAM-1 positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L and BAFF. Mol Immunol 2007; 44:1606-12; http:// dx.doi.org/10.1016/j.molimm.2006.08.021
8. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukaemia through reversal of abnormally increased proliferation. Blood 2002; 99:3792-800; http://dx.doi.org/10.1182/blood.V99.10.3792
9. Tibullo D, Giallongo C, La Cava P, Beretta S, Stagno F, Chiarenza A, et al. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009; 37:461-8; http://dx.doi.org/10. 1016/j.exphem.2008.12.008
10. + haemopoietic cells. Leukemia 2000; 14:1652-60; http://dx.doi.org/10.1038/sj.leu.2401875